Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis

Ähnliche Einträge

• Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
  von: Branislav V. Bajkin, et al.
  Veröffentlicht: (2026)
• Multicentre Retrospective and Prospective Analysis of Data on Emicizumab and Factor VIII Prophylaxis in Children With Severe Haemophilia A: Egypt‐Compare Study
  von: Tamer Hassan, et al.
  Veröffentlicht: (2026)
• Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
  von: Nuchanun Kessakorn, et al.
  Veröffentlicht: (2024)
• TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
  von: Kagehiro Amano, et al.
  Veröffentlicht: (2025)
• Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
  von: Midori Shima, et al.
  Veröffentlicht: (2025)